Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 541927, 7 pages
Review Article

Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects

1Molecular Genetics Unit, G. Gaslini Institute, 16147 Genova, Italy
2Department of Pediatrics, Center of Excellence for Biomedical Research (CEBR), University of Genova, 16147 Genova, Italy

Received 9 March 2010; Accepted 19 April 2010

Academic Editor: Beata Lecka-Czernik

Copyright © 2010 Renata Bocciardi and Roberto Ravazzolo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Thiazolidinediones (TZDs), among which Rosiglitazone, are known agonists of the peroxisome-proliferator-activated receptor (PPAR ) commonly used for treatment of hyperglycemia. A recently published article describing a case report on a patient affected by Fibrodysplasia Ossificans Progressiva (FOP) treated with Rosiglitazone has prompted interest for careful analysis of the rational basis of such treatment. This article reviews the effects of PPAR agonists in relationship with various pathogenic steps that occur during the course of FOP by reviewing the particularly rich literature on the effects of Rosiglitazone, to underscore their relevance to FOP and to consider possible adverse effects.